The class of compounds developed herein could be suitable for the treatment of heart disease and myocardial infarctions by increasing VEGFA production. Both DNA and mRNA delivery are being tested in clinical trials for boosting VEGFA levels, with the mRNA delivery approach having the most promise. Interestingly, TGP-377 is a relatively small molecule compared to an mRNA . Although compounds such as mRNA can be effectively delivered to the failing heart to allow for local expression, the nature of miRNA-targeting may provide selectivity without directly delivering the therapeutic to affected tissues. That is, TGP-377's will only be effective in a limited number of tissues that express both miR-377 and Vegfa mRNA. Further, the increase in VEGFA production will have an upper limit based on the effect of miR-377 on Vegfa's translation, not simply compound dose. Our proteomics studies showed that TGP-377 exerts highly specific effects on the proteome. Although additional studies will be required to progress these compounds into animal models and later clinical studies, our data suggest that the compound shows promise for therapeutic development. There are wide number of indications to which RNA-targeted small molecule medicines will be applicable. Perhaps studies like these will illustrate that molecular design can provide potent and selective small molecules to specifically recognize RNA targets in cells.